Category Archives: Regenerative Medicine

The global regenerative medicine market size was estimated at USD +2 million in 2019 and is expected to witness a CAGR of +11% throughout the forecast period.

Regenerative Medicine can be defined as a process of replenishing or regenerating human cells, tissues or organs to restore or establish a normal function. This area contains a commitment to regenerate damaged tissues and organs by replacing damaged tissue or by encouraging the bodys own repair mechanisms to heal tissues or organs. Regenerative medicine may enable scientists to grow tissues and organs in the laboratory and implant them safely when the body cannot cure itself.

Request for Sample@

https://www.reportconsultant.com/request_sample.php?id=42636

Current estimates indicate that around one in three Americans could benefit from regenerative medicine. Regenerative Medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include cell therapies (injection of stem cells or progenitor cells); immune therapy and tissue engineering.

Top Key Players:-

Application:

Ask for Discount@

https://www.reportconsultant.com/ask_for_discount.php?id=42636

North America, Latin America, Middle East, Africa, and Europe have been inspected to get a portfolio of the Global Regenerative Medicine Market. According to Report Consultant, the global market is expected to grow in the forecast period. The market has been elucidated with different case studies as well as feedback from various professionals. With respect to different attributes such as Importance, Development in the global market has explained in an accurate and professional manner. The progress projections for different market segments are also highlighted in the research report.

Table of content:-

Enquiry before buying@

https://www.reportconsultant.com/enquiry_before_buying.php?id=42636

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative businesses in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered businesses all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

Contact us:

Rebecca Parker

(Report Consultant)

Overland Park,

United States

Contact No: +1 620-220-2270

sales@reportconsultant.com

http://www.reportconsultant.com

See the rest here:
Future Success of Regenerative Medicine Market Growth and Forecasting with Top Key Players like Acelity LP, Nuvasive, Vericel Corporation Osiris...

New Orleans, LA, November 18, 2019 --(PR.com)-- David Crais, CEO of CMG Carealytics, was invited to the 4th Cross-Industry Innovation Summit held at Johnson Space Center in Houston, Texas last week. An exclusive group of Chief Innovation Officers from NASA, the US Navy, Army, Columbia University Business School, Barnard College, Amazon, Google, Dow Jones, and other global organizations.

Held over three days last week at Johnson Space Center, the Cross Industry Innovation Summit is a deep dive into innovation theory and practice from venture capital, startups, and technology transfer to corporate innovation labs and research and development programs. Exploring the discovery and investigative process with manufacturing, development, and commercialization and adoption of emerging technologies, new ideas, and new program development, these business, social, and government leaders work hands on to share ideas and cultural outlook and framework to bring about advances to their domains and constituencies . This is the fourth year of the program and the fourth year David Crais was asked to participate.

CMG Carealytics, a product management and development firm specializing in scientific, medical, and complex systems and industries, is known as a leader in the innovation and commercialization field. Working with incubators, accelerators, R&D teams, tech parks, venture capital firms, and expert networks, CMG Carealytics founded and led by David Crais continues to spearhead new innovation methods and practices in quality engineering, agile, scrum, lean, buisness analysis, product management, and other sociotechnical methods and in technologies from biotech, regenerative medicine, medical device, digital medicine, personalized medicine, printed electronics, imaging, thermography, and other technologies.

Crais has been engaged in innovation theory since his university education in scientific history and social change up to his development of medical technologies and taking them to market as publicly traded companies, private placements, new product launches, non-profits, and with economic development initiatives.

His participation in the Cross-Industry Summit with NASA is in addition to his work in serving on the Master Plan Task Force with Stennis Space Center in Mississippi, as a board member on the LSU Stephenson Entrepreneurship Institute, an advisor to Nevada State College Entrepreneurship Program, UC Irvine Medical Technology Commercialization Program, and with organizations like the Urban Land Institute, Angel Capital Association, Association for Corporate Growth, and other roles.

Contact Information:CMG CarealtyicsDavid Crais773-398-4143Contact via Emailcraisgroup.comghartman1@hotmail.com

Read the full story here: https://www.pr.com/press-release/799655

Press Release Distributed by PR.com

Go here to read the rest:
David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit - Benzinga

NEW YORK, Nov. 18, 2019 /PRNewswire/ --

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

The major drivers contributing to the growth of the global cell and gene therapy market are the growing incidence of several chronic and terminal diseases, including cancer, the launch of new products, the increasing availability in clinical evidences of these products in terms of safety and efficacy, the rapid adoption of CAR T-cell therapy, favorable regulatory support in the development of these treatment, and improved manufacturing expertise in these products.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increased Pool of Patient Population with Several Ailments Favorable Regulatory Support and Increasing Special Designations for Cell and Gene Therapy Products Growing Demand for CAR T-cell Therapy Products Increasing Strategic Acquisition Activities

The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018?2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Cell and Gene Therapy Market: Segmentation

This research report includes detailed market segmentation by product, application, end-user, and geography. The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. The segment is likely to witness upward growth on account of expanded expertise in the manufacturing of stem cell-based products.

The gene therapy segment is expected to witness faster growth as the penetration of these products is increasing at a significant rate, especially in developed economies. The market is expected to grow during the forecast period due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.

The oncology segment accounts for the highest share of the global market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient's life, thereby decreasing the mortality rate. The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products. The dermatology segment is likely to showcase growth due to the high product availability of wound care products in the market.Hospitals are the leading end-user segment. The segment is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.

Market Segmentation by Products Cell Therapy Gene TherapyMarket Segmentation by Distribution Channel Type Oncology Dermatology Musculoskeletal OthersMarket Segmentation by End-users Hospitals Wound Care Centers Cancer Care Centers Ambulatory Surgical Centers Others

Geographical Insights

The US market dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. There is also comparably high utilization and wide accessibility of these therapies. The oncology segment is likely to witness significant growth in North America.The market in Europe is expected to witness upward growth in the near future on account of the growing prevalence of chronic diseases and rising elderly population. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally.

Market Segmentation by Geography North Americao USo Canada APACo Japano Chinao South Koreao Australia Europeo Germanyo Franceo UKo Spaino Italy Latin Americao Brazilo Mexico MEAo Turkeyo Saudi Arabiao UAE

Key Vendor AnalysisThe global market is characterized by the presence of a few global, large-scale companies and several small to medium-scale companies offering one or two cell and gene therapy products. Global players are majorly offering innovative products with the potential of disease-modifying characteristics that are generating significant revenues, especially in Europe and US regions. Most innovative and breakthrough products are approved in the European countries and the US. Vendors are targeting mostly developed economies such as the US, Germany, France, the UK, Spain, and Japan as the uptake of these products is higher in these countries than low and middle-income countries. However, the market in these regions is at the nascent stage.

Key Vendors Gilead Sciences Spark Therapeutics Novartis AG Organogenesis Amgen Osiris Therapeutics Dendreon Vericel

Other Prominent Vendors Anterogen Tego Sciences Japan Tissue Engineering JCR Pharmaceuticals Medipost MolMed AVITA Medical CollPlant Corestem Biosolution Stempeutics Research Orchard Therapeutics Takeda Pharmaceutical Company CHIESI Farmaceutici CO.DON AnGes GC Pharma JW CreaGene APAC Biotech Nipro Corp. Terumo Orthocell bluebird bio

Key Market InsightsThe report provides the following insights into the market for the forecast period 20192024. Offers sizing and growth prospects of the market for the forecast period 20192024. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the market. Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read more from the original source:
The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 - PRNewswire

Date: 10th 11th March 2020 Location: London UK

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, we would be focusing on the pre-clinical, manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. This Congress event will be held on 10th and 11th March 2020 in London -UK

Regenerative therapies are proving its acceptance in the potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide an illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

Get Register and Download the Agenda at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/

Key Pointers 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

Conference Registration

Lets get you sorted! Choose which applies best to you @ https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/register

Read the original:
4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress held by MarketsandMarkets - ccsentinel.com

I am my own harshest critic when it comes to my physical flaws. I dont think thats uncommonwe all see parts of ourselves that others are blind to. My large, hooked nose has always bothered me. While Ive learned to appreciate its size, Ive never grown fond of the large bump. Additionally, at the ripe young age of 28, I have significantly more forehead wrinkles than anyone else my age. Yes, I wear sunscreen, but Im also a very expressive person, particularly when it comes to my eyebrows. My expressiveness has also manifested in prominent crow's feet.

While Im not opposed to aging and think wrinkles and crow's feet are attractive, its bizarre how many I have considering Im still in my twenties. I also know these things only get worse over time. I will say without shame that I dont want to have a withered and leathered face by the time Im 40. Because of this, I decided to make an appointment with Dr. Jessie Cheung, a board-certified dermatologist specializing in aesthetics, hormones and sexual health, and regenerative medicine.

When I arrived for my appointment, Dr. Cheung warmly greeted me, her face glowing like a cherub. She ushered me into her office and asked what Id like to get done. Its a bizarre question, when you think about it. The essence of what she was asking was: How can I change your face?

After explaining that Id like to get rid of my wrinkles and maybe add a little lip for fun (I have zero upper lip), she said she could do that without a problem. Then, she asked if she could make a few suggestions. This was the moment that I learned I'm actually not my own harshest critic.

It turns out, the left side of my chin is larger than the right side. My cheekbones have sunken in and my jawline could be stronger. There was more, but Ill save you from hearing it all.

Its wild: Ive looked at my face tens of thousands of times and had never noticed these things. Even when she pointed them out, I didnt really see them. Dr. Cheung then said that with a few fillers, she could straighten the bump on my noseit sounded too good to be true.

After all of her suggestions, I had a bit of an internal panic attack. It wasnt because I was becoming more aware of my flaws or, perhaps we should say, the areas of my face that could be improved upon. It was more that I was worried that my face would look completely different and I like my face. I didnt want someone elses face. I wanted mine, just a little smoother.

So, I expressed my reservation and repeatedly asked if all this work would look natural. Clearly, I wasnt the first person Dr. Cheung had seen with reservations, because she took my questions in stride. Even with her reassurance, I couldnt shake the feeling that Id come out looking like Donatella Versace. But then, when she said we could start with less and add more, I said, Screw it. Im here, load my face up. Besides, it only lasts roughly 4-6 months. So, if I didnt like it, I figured I could just become a shut-in during the cold winter months. Not the end of the world.

First, she numbed my face. Then, she started poking me with a syringe and loading me up with various fillers. Ill admit, it hurt a bit more than I thought it would. However, you can take breaks and the pain shouldnt deter you if you want to get this type of work doneits not that bad.

She stuck me for about an hour, hitting almost every part of my face. Throughout, shed stop and show me what she was doing, asking if I wanted more. Sometimes I said yes, other times I said noespecially when she worked on my lips. I knew that big, plump lips would make me look like a clown and, personally, I just dont care for that fake lip look.

Finally, I was done. When I looked in the mirror, it was scary. My face was so numb that I could barely move it. There was also some blood and injections swell for a few days before going down, so I liked really puffy. But, I will say, the bump on my nose had vanished. It was absolutely bewildering and incredible. As someone who has been self-conscious about my nose for years, it was exhilarating to see a change so quickly.

The first two days after all the injections was hard. It was tough to eat because it hurt to clench my jaw. But each day the pain lessened and by day three, nearly everything had settled. By day five, I looked how I look nowand let me tell you, Im damn stunning. Most of my wrinkles are gone and my face is far more symmetrical than it was before. When I take a photo, my cheekbones hit the light and pop. And dont even get me started on my nose!

Heres the thing: Most folks cant even tell Ive gotten work done, which is what I hoped for. Some friends who have either gotten their own work done or who want to get some done could telland they gushed over the results. And, of course, a few friends say, Why did you do that? I loved how you looked. The answer is, I didnt do it for themI did it for me. I did it to feel more comfortable in my skin.

All in all, I dont see much downside in getting fillers. I loved itwhich means I am going to have to go back to Dr. Cheung every 4-6 months. I see it as a small price to pay for the confidence it gave me.

Like what you just read? Youll love our magazine! Go here to subscribe. Dont miss a thing by downloading Apple News here and following Prevention. Oh, and were on Instagram too.

Go here to see the original:
I Got Fillers to Fix the Bump on My Noseand It Was Bizarre and Incredible - Prevention.com

CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for its third quarter ended September 30, 2019.

Third Quarter 2019 Financial Summary:

Third Quarter 2019 and Recent Highlights:

We delivered another quarter of significant year-over-year revenue growth across both our Advanced Wound Care and Surgical and Sports Medicine portfolios, said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. We grew our customer base across both portfolios and leveraged PuraPlys pass through advantage to gain new accounts, drive PuraPly adoption deeper into existing accounts and drive sales of our non-PuraPly products to existing PuraPly accounts. Strong execution also drove year-over-year growth of commercially available non-PuraPly products across our customer base. I am very pleased that despite amniotic capacity constraints, we successfully leveraged our diversified portfolio to deliver a solid quarter.

Mr. Gillheeney, Sr. continued: With continued execution against our PuraPly commercial strategy and improved amniotic capacity exiting Q3, we expect a strong finish to the year. We have updated our full-year 2019 revenue guidance and now expect to grow in a range of 31% to 34%. We remain committed to delivering on our mission to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care.

READ THE REST HERE

More:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results - OrthoSpineNews

Topline results expected before the end of Q1/2020

Rehovot, Israel and New York, NY (GLOBE NEWSWIRE) - Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimers blood diagnostic Lymphocyte Proliferation Test (LymPro Test) with amyloid PET neuroimaging at Leipzig University in Germany (the LymPro PET 2). Topline results are expected before the end of the first quarter of 2020.

Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimers disease, as confirmed with amyloid PET neuroimaging and other Alzheimers disease biomarkers. LymPro measures cell cycle dysregulation in peripheral lymphocytes. The top-line data, announced in July 2019, revealed a strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216). Breakthroughs academic collaborators at the Leipzig University then expanded enrollment of that study to include an additional cohort of 20 subjects (LymPro PET 2) to confirm the strong relationship seen from LymPro PET 1. The data from both LymPro 1 and LymPro 2 will be published together in a peer-reviewed journal in 2020.

LymPro is a unique immune system-based Alzheimers blood test, said Dr. Herman Weiss, President & CEO of Todos. LymPro could prove to be a major breakthrough for Alzheimers disease diagnosis by measuring cell cycle dysregulation and amyloid, together, conveniently as part of a blood workup in routine clinical practice. The therapeutic field in Alzheimers has begun to see some renewed hope based upon recent Aducanumab data announced by Biogen that is directly related to the amyloid hypothesis, as well as conditional approval by the National Medical Products Administration in China for the first new Alzheimers drug in over 20 years, called Oligomannate from Shanghai Green Valley Pharmaceuticals, that is based on gut-brain biology of the microbiome and its effects on the immune system. We believe this renewed optimism and broadening of pathophysiological hypotheses relevant to Alzheimers disease being evaluated in the clinic significantly increases the scope for LymPro pharma services collaborations and begins to refine LymPros clinical utility profile for primary care physicians as strategies to correct cell cycle dysregulation emerge.

About Alzheimer's DiseaseAccording to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050.

About Dr. Arendt's Research at Leipzig UniversityDr. Thomas Arendt is Professor of Neuroscience at Leipzig University where he runs the Paul Flechsig Institute of Brain Research. He has a 30-year record in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and made several seminal contributions to therapeutic concepts of Alzheimer's disease, including stem cell therapy and modulating tumor suppressor genes. In the early 1980's, he was involved in identifying the degeneration of the cholinergic system in Alzheimer's disease laying the basis for today's only available treatment. He is one of the pioneers of the "cell-cycle theory" of Alzheimer's disease, which he developed towards a diagnostic and therapeutic concept.

About Breakthrough Diagnostics, Inc.Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test, a diagnostic blood test for Alzheimers disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.

The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

About Todos Medical Ltd.Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancers influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The companys two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test, a blood test for diagnosing Alzheimers disease.

For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com

About Amarantus Bioscience Holdings, Inc.Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Companys 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimers blood diagnostic LymPro Test from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise and Parkinsons diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos. The transaction is expected close before the end of the first quarter of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc., a healthcare data-generating technology company that specializes in biomarker assay services that target multiple areas of oncology. Avant provides precision oncology data through its TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders, initially for breast cancer, to over 70 FDA-approved drug treatments.

AMBS 50%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimers aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza Group in 2015. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriners Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinsons disease. MANF was discovered by the Companys Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Amarantus has entered into a binding letter of intent to license the therapeutic assets from Elto Pharma, Cutanogen and MANF Therapeutics to Emerald Organic Products.

Forward-looking StatementsCertain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

2019 GlobeNewswire, Inc. All Rights Reserved.

SOURCE: Todos Medical Ltd.

Read more from the original source:
Todos And Amarantus JV Announces Full Enrollment For Clinical Trial Of LymPro Alzheimer's Blood Test Relationship With Amyloid PET - Laboratory...

The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.

Read a summary of the FDAs decision and all of lasts weeks top stories in hematology/oncology.

FDA grants CAR T-cell therapy regenerative medicine advanced therapy designation for multiple myeloma

The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma. Read more.

National Comprehensive Cancer Network's off-label cancer treatment recommendations constitute a problem

HemOnc Today spoke with Vinay K. Prasad, MD, MPH, about recommendations from the National Comprehensive Cancer Network for off-label cancer therapies, which he says are based on little or no evidence. Read more.

Study suggests National Comprehensive Cancer Network off-label recommendations valid based on available evidence

HemOnc Today also spoke with Razelle Kurzrock, MD, who contends that recommendations from the National Comprehensive Cancer Network for off-label cancer therapies are valid. Read more.

Studies show oncologists can adapt quickly to new evidence

As emerging cancer treatments continue to be approved at a rapid pace, published findings suggest that oncologists, who are reputed to be slow to change, can quickly adjust practice based on post-approval safety data or when novel cancer therapies enter the market. Read more.

Access to care among critical priorities for American Cancer Societys new chief medical, scientific officer

William G. Cance, MD, has begun his new role as American Cancer Societys chief medical and scientific officer. In an interview with HemOnc Today, Cance spoke about his priorities in his new role, the challenges he anticipates and how he hopes to meet them and his expectations for the oncology field in the coming years. Read more.

Original post:
FDA acts on CAR T-cell therapy, other top stories in hematology/oncology - Healio

Doris A. Taylors so-called replacement ghost heart suggests something otherworldly, but the eerie-looking form is far from an apparition. Its an innovative approach to organ transplantation that has inspired many in the medical community and at least one artist.

The Texas researchers process piggybacks on natures sophisticated design. Together she and a team of researchers strip cells off human and animal cadaver hearts with a soapy solution, leaving ghostly white protein shells that retain the form of the organ. They inject them with a patients blood or bone-marrow stem cells, and the ghost hearts act as scaffolding on which the newly introduced cells can slowly transform into a beating muscle.

What we said was, Wouldnt it be really cool if we could wash the sick cells out and put the healthy cells back in? said Taylor, director of Regenerative Medicine Research and director of the Center for Cell and Organ Biotechnology at the Texas Heart Institute, during a recent talk at the Radcliffe Institute for Advanced Study.

The hope is that one day these regenerated hearts will resolve the most challenging issues transplant patients currently face: the lack of a permanent artificial replacement, concerns about rejection, and the shortage of viable donor hearts.

Taylors efforts are driving what could become a revolution in organ transplants, and they have sparked the creativity of transdisciplinary artist Dario Robleto, whose latest work, on view at the Johnson-Kulukundis Family Gallery in Radcliffes Byerly Hall, recreates in images and sounds the original pulse wave of the heart first captured in visual form by scientists in the 1900s. Robleto and Taylor, longtime friends and Texas residents, explored those connections during Mondays Radcliffe discussion, which was moderated by Jennifer Roberts, Elizabeth Cary Agassiz Professor of the Humanities.

Robletos exhibit, Unknown and Solitary Seas, touches on the overlap between the medical mysteries and workings of the vascular pump, and the metaphor for the heart as the emotional center of the soul. It includes a video installation that features recreated sounds of a beating heart from the 19th century, reconstructed images of how the earliest pulse waves first appeared on the page, and a series of heart waveform sculptures in brass-plated stainless steel.

Roberts said that with his work, Robleto acknowledges the pulse waves promise, their profundity, their scientific value, but he also reclaims some of their ambiguity and asks us to wonder whether we can or should accept that these waveforms have escaped the realms of art, culture, and emotional communication.

Taylor similarly views her work as a blend of the scientific and the human. It transcends complicated, complex science, she says, in that her ghost hearts require a kind of passion, commitment, care, attention, and nurturing similar to whats required by a small child. Its really about building hearts at the emotional, mental, spiritual, and physical level that I think is going to get them to work, she said.

For Robleto, big ideas, like the creation of a new human heart, require multiple perspectives.

The artist called Taylors work one of the most fascinating and definitely one of the most emotional things Ive ever seen. As an object, he added, the ghost heart is stunningly beautiful but it also raises questions about the self, identity, emotion, the notions of form and where memory is truly held, questions he thinks artists can help address. He cited two of the nations earliest heart transplants, after which the patients wives asked their husbands, who had received donor hearts, if they still loved them.

Taylors work, Robleto said, is right at the edge of identity and materiality and so when the day comes when someone says the first ghost heart transplant I think we will have a similar moment where perhaps we will be forced to re-evaluate what we ask from our heart metaphor.

Dario Robletos Unknown and Solitary Seas is on view in Byerly Halls Johnson-Kulukundis Family Gallery through Jan. 18, 2020.

Follow this link:
An artist and a transplant researcher discuss the heart - Harvard Gazette

Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix.

Boca Raton, FL, November 09, 2019 --(PR.com)-- Remodem is a company offering an innovative product with an interesting mechanism of action.

A new molecule, external inorganic gel liquid magnet, has been developed using a combination of silica, calcium chloride, and tetrahydropiperine, which have a very high water holding capacity. External inorganic gel liquid magnet is a new generation, patented molecular structure with a high hydrophilic feature that is not likely to be absorbed into the skin.

It is applied as a layer with a minimum thickness of 3mm to cover the entire edema area that occurs after tissue trauma. The area of application is then covered with sterile bandage for twelve hours.

This unique product, Remodem Superficial Swelling Reducing Gel, helps to reduce swelling and discoloration that occur due to sprain, muscle strain, trauma, sports injury, as well as aesthetic and plastic surgeries. As Remodem is used in many fields of medicine, this partnership will bring the Remodem product line to GRGs network of professionals around the world and allow the company to reach its full potential.

With its beginnings in a small workshop, Aurafix has continually improved itself by paying attention to the importance of quality, workmanship, and superior service as well as investing in human capital and technology. Aurafix has been an application center in the fields of orthesis, prosthesis and rehabilitation since 2002.

The Aurafix products are focused in three areas: Orthopedics, Liposuction, and Compression. All of the products manufactured are flawlessly delivered to users using a strict quality control process that ensures accordance with the relevant standards:

- Adhesive VELCRO surfaces provide comfort and ease of use.- Flexible neoprene material provides ease of movement and a warming, soothing effect along with high strength. Increased body temperature accelerates the healing process by increasing blood circulation.-A flexible cotton fabric with high air permeability. The flexible structure provides the required support and comfort by wrapping the body.

The company continues to grow and operate as a leading brand name in the domestic market. By partnering with Global Regenerative Group, Aurafix will become a worldwide recognized brand.

Aurafix offers 240 different Orthopedic products, 50 Liposuction, and 50 Compression products.

For full product list please see the catalogues:

- Aurafix Orthopedics- Aurafix Liposuction- Aurafix Compression

Of the agreement, the President of Global Regenerative Group, Randolph Beimel said, The Global Regenerative Group is a medical community comprised of doctors, scientists, hospital administrators, businessmen, and entrepreneurs in more than 35 countries; all focused on developing the newest and most innovative products to provide the best possible outcomes for the patient. The GRG relationships around the world give us the opportunity to identify the highest quality products in a particular country and distribute them globally. The international launch of the Aurafix and Remodem product lines will offer patients on four continents the same benefits that patients in Turkey have experienced for many years.

Global Regenerative Group is a fast-growing company, collaborating with specialists and clinics around the world, with the primary purpose of delivering innovative medical care to the patient. During the last decade the company has developed extensive experience in the most advanced medical device industries. Recently, the company's emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies.

Global Regenerative Trade, a subsidiary of Global Regenerative Group, is dedicated to bringing science in practice through product development. Our main mission is supporting and accelerating the healing process following medical treatment by enhancing the bodys own capabilities. Global Regenerative Trade serves as a hub, bringing together products used in various fields of medicine. Using cumulative knowledge and expertise in the field of Regenerative medicine, we develop products which enhance the quality of life of patients and are more user-friendly for doctors.

Contact Information:Global Regenerative GroupRandy Beimel954-778-2581Contact via Emailglobalregenerative.group

Read the full story here: https://www.pr.com/press-release/798942

Press Release Distributed by PR.com

The rest is here:
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem - Benzinga